Newton, Massachusetts, November 11, 2024 – Abcuro, Inc., a clinical-stage biotechnology company developing therapies for the treatment of autoimmune diseases and cancer through precise modulation of cytotoxic T cells, today announced that Alex Martin, Chief Executive Officer, will present at the following investor conferences. Stifel 2024 Healthcare Conference: Presentation on November 18, 2024, at 3:00 pm READ MORE The post Abcuro Announces Participation in Upcoming Investor Conferences appeared first on Abcuro .